Tomas Crha

Dr. Tomas Crha

Department of Obstetrics and Gynecology, University Hospital Brno, Brno, Jihomoravský Kraj, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TCTomas Crha
Tomas Crha
POPetra Ovesna
Petra Ovesna
VWVit Weinberger
Vit Weinberger
MFMichal Felsinger
Michal Felsinger
BBBranislav Babjak
Branislav Babjak
LMLubos Minar
Lubos Minar
Background: Endometrial carcinoma is the most common gynaecological malignant tumour in developed countries. At present, no routinely used serum biomarker is available for the prediction of lymph node metastasis (LNM). This study thus evaluates the potential of tumour markers CA125 and HE4 as LNM predictors in endometrial carcinoma patients. Objectives: The aim of this study was to evaluate the potential use of CA125 and HE4 and to assess the viability of a model developed using the parameters of serum tumour marker levels for LNM risk stratification. Methods: A retrospective, single-institution study of 220 patients with biopsy-proven endometrial carcinoma was conducted from May 2020 to December 2023. Preoperative serum levels of HE4 and CA125 were determined. All patients underwent surgical lymph node staging. The study evaluated the sensitivity and specificity of tumour markers and of the developed LNM risk prediction model. Results: No LNM was observed in 167 of the 220 patients (75.9%), micrometastatic lymph node involvement was observed in 13 patients (5.9%), and macrometastatic involvement was observed in 24 patients (10.9%). Median CA125 and HE4 levels were significantly higher in patients with LNM than in those without. With a CA125 cut-off value of 35 IU/mL, a sensitivity of 70% and a specificity of 92% were obtained, while an HE4 cut-off value of 103 pmol/L yielded a sensitivity of 78% and a specificity of 80%. A prediction model combining CA125, HE4, and the extent of uterine invasion, as detected by ultrasound, yielded a sensitivity of 84% and a specificity of 98% in predicting LNM. Conclusions: CA125 and HE4, along with the prediction model, facilitate endometrial carcinoma patient subdivision into low- and high-risk LNM groups. As this method is technically simple, non-invasive, and inexpensive, it could be of undeniable benefit in the risk stratification of patients with multiple comorbidities, which limit the duration and extent of surgery.

26 April 2022 in Česká gynekologie
Verified
Journal Article
Closed access
KCKarel Crha
Karel Crha
Michal JešetaMichal Ješeta
Michal Ješeta
RPRadovan Pilka
Radovan Pilka
MKMarek Kašík
Marek Kašík
LMLenka Mekiňová
Lenka Mekiňová
TCTomas Crha
Tomas Crha
Objective: The goal of this article is to present the current knowledge of Klinefelter syndrome and its impact on male reproductive function as well as the current treatment options. Methods: PubMed/Medline, WoS and Scopus were searched for articles indexed until November 2021. Text: Klinefelter syndrome is a chromosomal aberration with an additional X chromosome in males. This may adversely affect testicular growth and spermatogenesis, thus resulting in male infertility. Recently, new knowledge has appeared about the treatment of male infertility. Conclusion: Interdisciplinary approach enables early diagnosis and treatment of patients with Klinefelter syndrome. Assisted reproductive technology is essential for infertility treatment in patients with Klinefelter syndrome.

29 August 2023 in Česká gynekologie
Verified
Journal Article
Closed access
TCTomas Crha
Tomas Crha
LMLubos Minar
Lubos Minar
MFMichal Felsinger
Michal Felsinger
VWVit Weinberger
Vit Weinberger
Objective: A comprehensive overview of therapeutical strategies for recurrent endometrial cancer with illustrative case report. Methodology: A review providing basic overview of therapeutical options for different forms of recurrent endometrial cancer including surgical treatment, systemic treatment and radiotherapy. It includes a case report presenting a treatment of patient with an endometrial cancer recurrence in the abdominal wall. Conclusion: Therapeutical strategies in patients with endometrial cancer recurrence include surgical treatment, radiotherapy and systemic treatment depending on previous therapy, type and site of recurrence or dissemination, performance status and wishes of the patient. Decision about choice of treatment should be individually discussed and evaluated by multidisciplinary oncogynecological commission board. Key words: endometrial cancer – local recurrence – distant recurrence – systemic treatment – radiotherapy – surgery

30 August 2024 in Česká gynekologie
Verified
Journal Article
Closed access
TCTomas Crha
Tomas Crha
VWVít Weinberger
Vít Weinberger
LMLuboš Minář
Luboš Minář
MFMichal Felsinger
Michal Felsinger
MBMarkéta Bednaříková
Markéta Bednaříková
JHJitka Hausnerová
Jitka Hausnerová
Objective: A comprehensive overview of surgical treatment of recurrent gynecological malignancies. Recurrent breast malignancies are not included in this review. Methodology: A review providing overview of surgical treatment options for recurrent malignancies of adnexa of the uterus (ovary, fallopian tube), uterine corpus, uterine cervix, and carcinoma of the vagina and vulva. Conclusion: Optimal surgical treatment for patients with recurrent cancer is based on multidisciplinary approach with stratification according to individual prognostic markers. These include patient’s performance status, outcome of primary surgery, current extent of recurrence, and histopathological, molecular, and biochemical characteristics. Decision about choice of treatment should be individually discussed and evaluated by the multidisciplinary oncogynecological commission board. Key words: endometrial cancer – cervical cancer – vulvar cancer – ovarian cancer – recurrent cancer – surgery